We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-0.93%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.68B
AUM Growth
-$472M
Cap. Flow
-$289M
Cap. Flow %
-10.8%
Top 10 Hldgs %
51.96%
Holding
86
New
15
Increased
18
Reduced
20
Closed
23

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$97.1M
2
DVAX
Dynavax Technologies
DVAX
+$63.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$56M
4
HRMY icon
Harmony Biosciences
HRMY
+$49.8M
5
IMVT icon
Immunovant
IMVT
+$46.9M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$198M
2
NTLA icon
Intellia Therapeutics
NTLA
+$102M
3
ALKS icon
Alkermes
ALKS
+$98M
4
VRNA
Verona Pharma
VRNA
+$87.5M
5
AXSM icon
Axsome Therapeutics
AXSM
+$77M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
1
DELISTED
Dynavax Technologies
DVAX
$227M 8.47%
17,791,486
+5,265,000
+42% +$63.7M
GH icon
2
Guardant Health
GH
$21.7B
$196M 7.32%
6,419,566
+419,006
+7% +$11.8M
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$167M 6.23%
2,000,000
+399,307
+25% +$32.8M
IMVT icon
4
Immunovant
IMVT
$7.93B
$149M 5.54%
6,000,000
+1,652,536
+38% +$46.9M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$136M 5.09%
4,274,921
-125,733
-3% -$3.78M
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$125M 4.66%
3,460,756
-383,144
-10% -$13.4M
CYTK icon
7
Cytokinetics
CYTK
$10.5B
$118M 4.39%
2,500,000
+1,870,094
+297% +$97.1M
OCUL icon
8
Ocular Therapeutix
OCUL
$1.79B
$110M 4.09%
12,836,282
+114,822
+0.9% +$1.12M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.09B
$86.7M 3.23%
4,522,741
+771,796
+21% +$16.8M
PLRX icon
10
Pliant Therapeutics
PLRX
$64.4M
$78.7M 2.93%
5,972,257
– –
GPCR icon
11
Structure Therapeutics
GPCR
$3.41B
$75.9M 2.83%
2,800,000
+1,579,492
+129% +$56M
IONS icon
12
Ionis Pharmaceuticals
IONS
$8.6B
$67.6M 2.52%
1,933,928
-266,072
-12% -$9.95M
NRIX icon
13
Nurix Therapeutics
NRIX
$2.41B
$56.5M 2.11%
3,000,000
-868,104
-22% -$19.9M
MBX
14
MBX Biosciences
MBX
$3.14B
$55.6M 2.08%
3,018,935
– –
ETNB
15
DELISTED
89bio
ETNB
$50.7M 1.89%
6,478,249
+3,711,737
+134% +$30.6M
HRMY icon
16
Harmony Biosciences
HRMY
$2.04B
$49.9M 1.86%
+1,450,000
New +$49.8M
DYN icon
17
Dyne Therapeutics
DYN
$4.7B
$47.1M 1.76%
2,000,000
-1,282,000
-39% -$37.9M
SEPN
18
Septerna Inc
SEPN
$1.55B
$43.8M 1.63%
+1,912,929
New +$45.2M
NMRA icon
19
Neumora Therapeutics
NMRA
$298M
$42.4M 1.58%
4,000,000
+3,432,572
+605% +$41.1M
GMAB icon
20
Genmab
GMAB
$17.7B
$41.7M 1.56%
+2,000,000
New +$43.9M
AKRO
21
DELISTED
Akero Therapeutics
AKRO
$41.5M 1.55%
1,490,000
+800,216
+116% +$24.2M
VRNA
22
DELISTED
Verona Pharma
VRNA
$39.5M 1.47%
850,000
-2,330,025
-73% -$87.5M
CLDX icon
23
Celldex Therapeutics
CLDX
$2.99B
$38.9M 1.45%
+1,540,132
New +$41.8M
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.79B
$38.6M 1.44%
+1,000,000
New +$43.6M
ANIP icon
25
ANI Pharmaceuticals
ANIP
$1.8B
$35.9M 1.34%
649,042
+144,214
+29% +$8.28M
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Deep Track Capital held 86 positions worth $2.68B, down 15% from $3.15B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deep Track Capital withdrew a net $289M in Q4 2024, closing 23 positions and reducing 20 holdings. Its most notable exit was argenx, an estimated $198M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Harmony Biosciences worth $49.9M.

  • Deep Track Capital's largest Q4 2024 buy was Harmony Biosciences: 1,450,000 shares worth $49.9M.
  • Deep Track Capital added most to Cytokinetics in Q4 2024, an estimated $97.1M increase.
  • Deep Track Capital's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $87.5M.
  • Deep Track Capital fully exited argenx in Q4 2024, selling an estimated $198M.
  • Deep Track Capital's ten largest holdings make up 52% of its $2.68B portfolio in Q4 2024.
  • Deep Track Capital opened 15 new positions and closed 23 in Q4 2024.
  • Deep Track Capital's portfolio value fell 15% quarter-over-quarter to $2.68B.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.